Systematic review report for question 17

PICO Question 17: For women have been treated for adenocarcinoma in situ (AIS) with cone excision or LEEP and with clear histologic margins what is the safety and effectiveness of cytology and HPV testing at 12 and 24 months and discharging if double-negative at both 12 and 24 months or completion hysterectomy compared to cytology?

Population	Study design	Intervention	Control	Outcomes
Women treated for AIS with cone excision or LEEP with complete excision and clear histologic margins	Randomized or pseudo- randomized controlled trial	Cytology and HPV testing 12 and 24 months after treatment with discharge if double negative on both occasions Or Completion hysterectomy	Annual cytology	Cervical cancer mortality Cervical cancer diagnosis Precancerous high grade lesion detection

AIS = adenocarcinoma in situ; LEEP = loop electrosurgical excision procedure

1. METHODS

1.1. Guidelines

Relevant recent (2005 onwards) guidelines were identified by scanning the citations identified by the literature search and searching the National Guideline Clearinghouse (http://guideline.gov/) and the Guidelines Resource Centre (www.cancerview.ca).

To be considered for adoption guidelines had to be directly relevant, based on systematic reviews of the evidence and meet the pre-specified criteria of scores of greater or equal to 70% for the domains rigour of development, clarity of presentation and editorial independence of the AGREE II instrument (http://www.agreetrust.org/resource-centre/agree-ii/).

1.2. Literature Search

Medline including articles in process, Embase, CENTRAL, Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment (HTA) databases, were searched for articles published from 2004 until 31st August 2015, using text terms and, where available, database-specific subject headings. In these databases searches for HPV were combined with searches for cervical lesions or cancer and their treatments, and where possible, database-specific filters for identifying randomized controlled trials and systematic reviews/meta-analyses of randomized controlled trials. To identify studies which considered Aboriginal and Torres Strait Islander (ATSI) peoples these searches were then coupled with search terms for ATSI peoples. A complete list of the terms used for search strategies are included as Appendix A. The Cochrane systematic review database was also searched for relevant systematic reviews or meta-analyses using the term "HPV", and abstracts for the 2015 EUROGIN conference were searched using the term "gland". Reference lists of relevant articles and guidelines were checked for additional potentially relevant articles.

1.3. Inclusion Criteria

Selection criteria	Inclusion criteria	
Study type	Intervention	
Study design	Randomised controlled trial (RCT) or pseudo-randomised controlled trial or Systematic reviews or meta-analyses of RCTs or pseudo-randomised	
	controlled trials	
Population	Women who have been treated for adenocarcinoma in situ	
Intervention	Cytology and HPV testing 12 and 24 months after treatment with discharge if double negative on both occasions Or Completion hysterectomy	
Comparator	Annual cytology	
Outcomes	Cervical cancer mortality or Cervical cancer diagnosis or CIN3+ including recurrent AIS detection	
Language English		
Publication period After 31 st December 2003 and before1 st September 2015		

AIS = adenocarcinoma in situ; CIN3+ = cervical intraepithelial neoplasm grade 3 or worse

Conference proceedings other than those from the EUROGIN 2015 were not included.

2. RESULTS

2.1. Guidelines

Four sets of guidelines (listed in Appendix C) were identified that contained potentially relevant recommendations. These recommendations either did not directly address the clinical question, were not based systematic reviews of the evidence or it was unclear as to whether they were based on systematic reviews of the evidence and thus were not adopted as they did not meet the pre-specified AGREE II criteria for adoption.

2.2. Results of Literature Search

Figure 1 outlines the process of identifying relevant articles for the systematic review. The searches identified a total of 305 citations. Titles and abstracts were examined however none of the articles identified were potentially relevant to the systematic review. Thus no studies were found that directly answered the clinical question and met the inclusion criteria for this systematic review. As such there were no studies of Aboriginal and/or Torres Strait Islander women that met the inclusion criteria.

Database or Source	Number of Citations	Number of Articles Collected	Number of Articles Included	ATSI filter results
Medline, PreMedline, CENTRAL and Embase	224	0	0	N/A
HTA and DARE	7	0	0	N/A
Cochrane database of systematic reviews	74	0	0	N/A
EUROGIN 2015 abstracts	0	0	0	N/A
Total	305	0	0	N/A




Figure 1. Process of inclusion and exclusion of studies

APPENDICES

Appendix A: Search strategies used

For Medline, PreMedline, Embase and CENTRAL databases (via Ovid):

1 Uterine Cervical Neoplasms/ 2 Cervical Intraepithelial Neoplasia/ 3 CIN*.mp. 4 (cervi* adj5 (cancer* or tumor* or tumour* or malignan* or neoplas* or carcinoma* or adenocarcinoma* or precancer or pre-cancer*).mp. 5 AIS.mp. 6 Adenocarcinoma in Situ/ 7 (adenocarcinoma* adj5 endocervi*).mp. 8 1 or 2 or 3 or 4 or 5 or 6 or 7 9 excision*.mp. 10 surg*.mp. 10 cone biops*.mp. 11 cone biops*.mp. 12 (cone adj3 biops*).mp. 13 coni?ation.mp. 14 (LEEP or LLETZ or SWETZ or NETZ).mp. 15 loop electro-excisional procedure.mp. 16 laser.mp. 17 Fischer cone.mp. 18 electro-surg*.mp. 19 recurrent.mp. 20 "test of cure*.mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 25 HPV.mp. 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomaviris Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 34 placebo.ab.	#	Searches
CIN¹.mp. (cervi* adj5 (cancer* or tumor* or tumour* or malignan* or neoplas* or carcinoma* or adenocarcinoma* or precancer* or pre-cancer*)).mp. AlS.mp. Als.mp. Adenocarcinoma in Situ/ (adenocarcinoma* adj5 endocervi*).mp. 1 or 2 or 3 or 4 or 5 or 6 or 7 excision*.mp. surg*.mp. cone biops*.mp. (cone adj3 biops*).mp. (cone adj3 biops*).mp. (lEEP or LLETZ or SWETZ or NETZ).mp. loop electro-excisional procedure.mp. laser.mp. Fischer cone.mp. electro-surg*.mp. recurrent.mp. vest of cure*.mp. (reat* adj5 surveillance).mp. (post-treatment or posttreatment).mp. (reat* adj5 follow*).mp. Application* papillomavir*.mp. papillomavir*.mp. Application* A	1	Uterine Cervical Neoplasms/
(cervi* adj5 (cancer* or tumor* or tumour* or malignan* or neoplas* or carcinoma* or adenocarcinoma* or precancer* or pre-cancer*)).mp. AIS.mp. AIS.mp. (adenocarcinoma in Sittu/ (adenocarcinoma* adj5 endocervi*).mp. 1 or 2 or 3 or 4 or 5 or 6 or 7 excision*.mp. (cone adj3 biops*).mp. (leEP or LLETZ or SWETZ or NETZ).mp. (bleep or LLETZ or SWETZ or NETZ).mp. Is loop electro-excisional procedure.mp. laser.mp. Fischer cone.mp. electro-surg*.mp. recurrent.mp. 'test of cure*.mp. (treat* adj5 sulveillance).mp. (treat* adj5 follow*).mp. yor 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 HPV.mp. papillomavir*.mp. hr\$HPV.mp. exp Papillomaviriane/ exp Papillomaviriane/ san 24 and 30 randomized controlled trial.pt.	2	Cervical Intraepithelial Neoplasia/
# precancer* or pre-cancer*).mp. Als.mp. Adenocarcinoma in Situ/ (adenocarcinoma adj5 endocerv*).mp. 1 or 2 or 3 or 4 or 5 or 6 or 7 excision*.mp. cone biops*.mp. (cone adj3 biops*).mp. coni?ation.mp. (interest or Nett or Ne	3	CIN*.mp.
6 Adenocarcinoma in Situ/ 7 (adenocarcinoma* adj5 endocervi*).mp. 8 1 or 2 or 3 or 4 or 5 or 6 or 7 9 excision*.mp. 10 surg*.mp. 11 cone biops*.mp. 12 (cone adj3 biops*).mp. 13 coni?ation.mp. 14 (LEEP or LLETZ or SWETZ or NETZ).mp. 15 loop electro-excisional procedure.mp. 16 laser.mp. 17 Fischer cone.mp. 18 electro-surg*.mp. 19 recurrent.mp. 20 *test of cure*.mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 EMPV.mp. 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomavirus Infections/ 29 exp Papillomaviriale/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	4	
7 (adenocarcinoma* adj5 endocervi*).mp. 8 1 or 2 or 3 or 4 or 5 or 6 or 7 9 excision*.mp. 10 surg*.mp. 11 cone biops*.mp. 12 (cone adj3 biops*).mp. 13 coni?ation.mp. 14 (LEEP or LLETZ or SWETZ or NETZ).mp. 15 loop electro-excisional procedure.mp. 16 laser.mp. 17 Fischer cone.mp. 18 electro-surg*.mp. 19 recurrent.mp. 20 "test of cure*.mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 HPV.mp. 26 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 34 p	5	AIS.mp.
8 1 or 2 or 3 or 4 or 5 or 6 or 7 9 excision*.mp. 10 surg*.mp. 11 cone biops*.mp. 12 (cone adj3 biops*).mp. 13 coni?ation.mp. 14 (LEEP or LLETZ or SWETZ or NETZ).mp. 15 loop electro-excisional procedure.mp. 16 laser.mp. 17 Fischer cone.mp. 18 electro-surg*.mp. 19 recurrent.mp. 20 "test of cure".mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 25 HPV.mp. 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomavirus Infections/ 29 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	6	Adenocarcinoma in Situ/
9 excision*.mp. 10 surg*.mp. 11 cone biops*.mp. 12 (cone adj3 biops*).mp. 13 coni?ation.mp. 14 (LEEP or LLETZ or SWETZ or NETZ).mp. 15 loop electro-excisional procedure.mp. 16 laser.mp. 17 Fischer cone.mp. 18 electro-surg*.mp. 19 recurrent.mp. 20 "test of cure*.mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 17 HPV.mp. 28 exp Papillomavir*.mp. 29 exp Papillomavirus Infections/ 29 exp Papillomavirus Infections/ 29 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	7	(adenocarcinoma* adj5 endocervi*).mp.
10 surg*.mp. 11 cone blops*.mp. 12 (cone adj3 blops*).mp. 13 coni?ation.mp. 14 (LEEP or LLETZ or SWETZ or NETZ).mp. 15 loop electro-excisional procedure.mp. 16 laser.mp. 17 Fischer cone.mp. 18 electro-surg*.mp. 19 recurrent.mp. 20 *test of cure*.mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 17 HPV.mp. 18 exp Papillomavir*.mp. 29 exp Papillomavirius Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	8	1 or 2 or 3 or 4 or 5 or 6 or 7
11 cone biops*.mp. 12 (cone adj3 biops*).mp. 13 coni?ation.mp. 14 (LEEP or LLETZ or SWETZ or NETZ).mp. 15 loop electro-excisional procedure.mp. 16 laser.mp. 17 Fischer cone.mp. 18 electro-surg*.mp. 19 recurrent.mp. 20 "test of cure".mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 25 HPV.mp. 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomavirus Infections/ 29 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	9	excision*.mp.
12 (cone adj3 biops*).mp. 13 coni?ation.mp. 14 (LEEP or LLETZ or SWETZ or NETZ).mp. 15 loop electro-excisional procedure.mp. 16 laser.mp. 17 Fischer cone.mp. 18 electro-surg*.mp. 19 recurrent.mp. 20 "test of cure*.mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 16 HPV.mp. 17 papillomavir*.mp. 18 exp Papillomaviridae/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	10	surg*.mp.
13 coni?ation.mp. 14 (LEEP or LLETZ or SWETZ or NETZ).mp. 15 loop electro-excisional procedure.mp. 16 laser.mp. 17 Fischer cone.mp. 18 electro-surg*.mp. 19 recurrent.mp. 20 "test of cure".mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 17 HPV.mp. 18 exp Papillomavir*.mp. 29 hr\$HPV.mp. 20 papillomavir*.mp. 21 hr\$HPV.mp. 22 axis axis follomavir*.mp. 23 last axis follomavir*.mp. 24 papillomavir*.mp. 25 randomized controlled trial.pt. 26 axis followarity.mp. 27 last axis followarity.mp. 28 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	11	cone biops*.mp.
14 (LEEP or LLETZ or SWETZ or NETZ).mp. 15 loop electro-excisional procedure.mp. 16 laser.mp. 17 Fischer cone.mp. 18 electro-surg*.mp. 19 recurrent.mp. 20 "test of cure*.mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 25 HPV.mp. 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	12	(cone adj3 biops*).mp.
15 loop electro-excisional procedure.mp. 16 laser.mp. 17 Fischer cone.mp. 18 electro-surg*.mp. 19 recurrent.mp. 20 "test of cure".mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 25 HPV.mp. 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	13	coni?ation.mp.
laser.mp. Fischer cone.mp. lelectro-surg*.mp. lelectro-surg*.mp. lelectro-surg*.mp. letst of cure".mp. letst of cure".mp. letterat* adj5 surveillance).mp. letterat* adj5 follow*).mp. letterat* adj6 follow*.mp. letterat* a	14	(LEEP or LLETZ or SWETZ or NETZ).mp.
17 Fischer cone.mp. 18 electro-surg*.mp. 19 recurrent.mp. 20 "test of cure".mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 25 HPV.mp. 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	15	loop electro-excisional procedure.mp.
lectro-surg*.mp. 19 recurrent.mp. 20 "test of cure".mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 25 HPV.mp. 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	16	laser.mp.
recurrent.mp. recurrent.mp. rest of cure".mp. freat* adj5 surveillance).mp. freat* adj5 surveillance).mp. freat* adj5 follow*).mp. recurrent.ment or posttreatment).mp. freat* adj5 follow*).mp. recurrent.ment or posttreatment).mp. recurrent.ment or posttreatment).mp. recurrent.ment. r	17	Fischer cone.mp.
"test of cure".mp. 21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 25 HPV.mp. 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	18	electro-surg*.mp.
21 (treat* adj5 surveillance).mp. 22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 25 HPV.mp. 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	19	recurrent.mp.
22 (post-treatment or posttreatment).mp. 23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 25 HPV.mp. 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	20	"test of cure".mp.
23 (treat* adj5 follow*).mp. 24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 25 HPV.mp. 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	21	(treat* adj5 surveillance).mp.
9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 HPV.mp. hr\$HPV.mp. exp Papillomavirus Infections/ exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	22	(post-treatment or posttreatment).mp.
25 HPV.mp. 26 papillomavir*.mp. 27 hr\$HPV.mp. 28 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	23	(treat* adj5 follow*).mp.
papillomavir*.mp. hr\$HPV.mp. exp Papillomavirius Infections/ exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	24	9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
hr\$HPV.mp. 28 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	25	HPV.mp.
28 exp Papillomavirus Infections/ 29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	26	papillomavir*.mp.
29 exp Papillomaviridae/ 30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	27	hr\$HPV.mp.
30 25 or 26 or 27 or 28 or 29 31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	28	exp Papillomavirus Infections/
31 8 and 24 and 30 32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	29	exp Papillomaviridae/
32 randomized controlled trial.pt. 33 controlled clinical trial.pt. 34 placebo.ab.	30	25 or 26 or 27 or 28 or 29
33 controlled clinical trial.pt. 34 placebo.ab.	31	8 and 24 and 30
34 placebo.ab.	32	randomized controlled trial.pt.
i i	33	controlled clinical trial.pt.
05 1 10 11	34	placebo.ab.
35 randomized.ab.	35	randomi?ed.ab.
36 randomly.ab.	36	randomly.ab.

37	trial.ab.		
38	groups.ab.		
39	32 or 33 or 34 or 35 or 36 or 37 or 38		
40	31 and 39		
41	limit 40 to (english language and female and humans and yr="2004 -Current")		
42	vaccine.mp.		
43	41 not 42		
44	remove duplicates from 43		

Used the Cochrane sensitivity maximizing filter for identifying randomized controlled trials (http://handbook.cochrane.org, accessed 12/09/2015)

ATSI search terms used

#	Searches
	((exp Australia/ OR Australia\$.ti,ab) AND (Oceanic ancestry group/ OR aborigin\$.ti,ab. OR indigenous.mp.)) OR torres strait\$ islander\$.ti,ab

From the Lowitja Institute at http://www.lowitja.org.au/litsearch-background-information accessed 30/09/2013)

For Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessments (HTA) databases (via Ovid):

#	Searches
1	Uterine Cervical Neoplasms/
2	Cervical Intraepithelial Neoplasia/
3	CIN*.mp.
4	(cervi* adj5 (cancer* or tumor* or tumour* or malignan* or neoplas* or carcinoma* or adenocarcinoma* or precancer* or pre-cancer*)).mp.
5	AIS.mp.
6	Adenocarcinoma in Situ/
7	(adenocarcinoma* adj5 endocervi*).mp.
8	1 or 2 or 3 or 4 or 5 or 6 or 7
9	excision*.mp.
10	surg*.mp.
11	cone biops*.mp.
12	(cone adj3 biops*).mp.
13	coni?ation.mp.
14	(LEEP or LLETZ or SWETZ or NETZ).mp.
15	loop electro-excisional procedure.mp.
16	laser.mp.
17	Fischer cone.mp.
18	electro-surg*.mp.
19	recurrent.mp.
20	"test of cure".mp.
21	(treat* adj5 surveillance).mp.
22	(post-treatment or posttreatment).mp.
23	(treat* adj5 follow*).mp.

24	9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25	HPV.mp.
26	papillomavir*.mp.
27	hr\$HPV.mp.
28	exp Papillomavirus Infections/
29	exp Papillomaviridae/
30	25 or 26 or 27 or 28 or 29
31	8 and 24 and 30

Appendix B:

NHMRC Evidence Hierarchy for Intervention studies

Level	Study design		
I	Meta-analysis or a systematic review of level II studies		
II	Randomised controlled trial or a phase III/IV clinical trial		
III-1	Pseudo-randomised controlled trial or a meta-analysis/systematic review of level III-1 studies		
III-2	Comparative study with concurrent controls: - Phase II clinical trial - Non-randomised, experimental trial9 - Controlled pre-test/post-test study - Adjusted indirect comparisons - Interrupted time series with a control group - Cohort study - Case-control study or a meta-analysis/systematic review of level III-2 studies		
III-3 A comparative study without concurrent controls: - Phase I clinical trial - Historical control study - Two or more single arm study10 - Unadjusted indirect comparisons - Interrupted time series without a parallel control group or a meta-analysis/systematic review of level III-3 studies			
IV	Case series with either post-test or pre-test/post-test outcomes or a meta-analysis/systematic revie of level IV studies		

According to the standards of the National Health and Medical Research Council

Appendix C:

Potentially relevant guidelines identified and reason why not adopted

Year	Organisation	Title	Reason why not adopted
2012	American Society for Colposcopy and Cervical Pathology.	Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors	Consensus based on literature searches and KPNC data
2012	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology	Screening guidelines for the prevention and early detection of cervical cancer.	Does not directly address the clinical question
2012	Society of Obstetricians and Gynaecologists of Canada	Colposcopic management of abnormal cervical cytology and histology.	Does not directly address the clinical question
2009	European Cancer Screening Network and European Cancer Network	European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, Part 2	Unclear as to whether recommendations were based on systematic reviews – full document no longer available at published website